Citarinostat is a selective histone deacetylase 6 (HDAC6) inhibitor currently under investigation for its potential in preclinical research and clinical trials, particularly for managing solid tumor cell… Read more
Citarinostat is a selective histone deacetylase 6 (HDAC6) inhibitor currently under investigation for its potential in preclinical research and clinical trials, particularly for managing solid tumor cell growth and exploring therapeutic drug synergies. As this compound advances through development, pharmaceutical laboratories require high-quality reference standards to ensure the accuracy of analytical testing and quality control processes. This category includes the Citarinostat active pharmaceutical ingredient alongside its critical related compounds, such as the N-nitroso impurity and stable isotope labelled versions like Citarinostat-d5. These materials are essential for impurity profiling, method validation, and rigorous stability studies, allowing researchers to accurately detect, quantify, and characterize potential degradation products and metabolites. Utilizing these specialized reference materials supports the development of reliable analytical methods necessary for monitoring the purity and consistency of this promising anticancer candidate throughout the drug development lifecycle.